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SYNDROMIC VIGNETTES IN ANAESTHESIA
SYNOPSIS OF PATIENTS
Case 1
A 14-year old male weighing 54.9kg, height 178cm, presented for
foot reconstruction. He had bilateral cavovarus deformities that were
painful. He was otherwise healthy. He first presented as a 7-year old
with some difficulty running, and a tendency to fall. He had walked
on his toes since he started walking at 14 months. He complained of
occasional cramps and pain in both legs that improved with
stretching exercises. He did physical exercise at school but could
not climb ropes. His handwriting was untidy and awkward. On
examination he had wasting of both calves, wasting of the thenar
eminence and the interossei of both hands and feet. Deep tendon
reflexes were absent. He had slight sensory changes in his hands
and feet (diminished temperature). He had facial symmetry, normal
eyelid closure and no evidence of other cranial nerve involvement
or autonomic disturbance (normal sweating, normal tears and
thermal regulation) A recent hip radiograph revealed mild hip
dysplasia on the right but this was asymptomatic. He was adopted
but was still in contact with his biological mother who had a strong
family history of peripheral motor and sensory neuropathy that had
been diagnosed as Charcot-Marie-Tooth (CMT) disease type 1. He
had undergone genetic testing which showed a duplication of the
peripheral myelin protein (PMP 22) gene consistent with CMT Type
1A. The previous anaesthetic for right foot surgery was reported to
be uneventful. On this occasion he was given a propofol induction,
maintained on sevoflurane in 35% oxygen, and a left popliteal nerve
block was placed using a nerve stimulator and 8ml 0.375%
bupivacaine. A saphenous nerve block was also performed using
5ml 0.375% bupivacaine. Anaesthesia was uneventful and the patient
was comfortable postoperatively
Case 2
A 19-year old boy weighing 64kg, height 179cm, presented for
removal of an osteophyte of his left hallux-interphalangeal joint, and
tendon transfer on his painful left foot. He had had numerous
reconstructive operations to both feet. He had a strong family history
of CMT on his mother’s side although she herself did not have
evidence of CMT. His symptoms had started some three years






loss in his lower limbs that was associated with muscle wasting in
both calves. He had no evidence of hip dysplasia or respiratory
difficulty. A previous DNA test had confirmed CMT Type 1A. He was
experiencing pain on the anterior aspect of the ankle that was worse
after 20 minutes of weight bearing. His foot sometimes got stuck in
eversion, and he was able to correct it himself. He had recently
suffered an infected ingrown toenail and had a callous under his 5th
metatarsal. Anaesthesia consisted of a sevoflurane induction and
maintenance was with sevoflurane in oxygen-enriched air (FiO
2
0.35). A continuous peripheral nerve catheter (Arrow ®) was placed
with the aid of a nerve stimulator. An initial dose of 8ml 0.5%
bupivacaine was used followed by a continuous infusion of 3ml.hr
0.25% bupivacaine. Anaesthesia was uneventful and the patient was
comfortable postoperatively. The catheter was removed after 48
hours.
Introduction
Charcot-Marie-Tooth disease is named after three neurologists.
Charcot and Marie first described this unusual slowly progressive
hereditary motor and sensory neuropathy in France in 18861. The
muscle atrophy was characterized by weakness and wasting of the
feet and leg muscles, followed by involvement of the hands. Tooth, in
England, also described this peroneal type of progressive muscular
atrophy with essentially the same clinical features in the same year.
Tooth correctly postulated correctly that the disease was due to a
neuropathy and not a myelopathy as was proposed by Charcot and
Marie.
CMT is the most common form of peripheral neuropathy in
children, with symptoms usually evident in the mid teens. Earlier
onset is uncommon but may be at any time between the first and
third decade. CMT is slowly progressive, with periods of remission
and exacerbations. The incidence in the USA is in the order of
1:25002 –3300,3 but CMT is found worldwide in people of all race
and ethnic groups. The worldwide incidence is estimated as
1:100004.
CMT disease is also referred to as peroneal muscular atrophy or
hereditary hypertrophic neuropathy. CMT has a heterogeneous
spectrum of inheritance and clinical presentation. Some family
members may have such a mild form of the disease that they are
unaware of the problem until they are evaluated because another
member of the family may have the disease. The challenge for the
clinician is to differentiate CMT from other neurological causes of
weakness and sensory loss in the “glove and stocking” distribution.
The exact nature of the disorder can be distinguished from other
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non-genetic causes of neuropathy by the age of onset, family history
and inheritance pattern, clinical examination, nerve conduction and
genetic studies.
Clinical Features
CMT is a group of conditions that affects the lower limbs resulting in
weakness and muscle wasting below the knees and in the feet,
causing significant foot deformities (Fig 1). Typically CMT is a slowly
progressive hereditary motor and sensory neuropathy with muscle
wasting and early loss of deep tendon reflexes. The hands may be
affected but this usually occurs later in the disease process.
The hallmark is peroneal muscle atrophy. The lower leg is classically
described as having an “ inverted champagne bottle” or “stork leg”
deformity. As a result of the weak dorsiflexors of the feet, patients
frequently trip over objects and have a tendency to sprain their
ankles. The foot drops with each step and forces the patient to lift
their knee (“equine gait”). Patients may complain of leg cramps
after long walks. The foot deformities usually precede the muscle
atrophy by some years.
 Many have a mild ‘sensory’ component’ resulting in a loss of
sensation (heat, cold and pain) in the glove and stocking distribution
on the hands and feet. Typically these patients have difficulty using
zippers and buttons and other tasks that require fine finger
movement. Handwriting is often clumsy and untidy. The abnormally
thick nerve may be palpable in the arms of some patients.
Autonomic dysfunction is impaired in some forms of the disease.
This manifests as impaired temperature regulation and absence of
sweating. The symptoms may be exacerbated in pregnancy,
probably by hormonally induced neuronal oedema. The symptoms
may return to baseline after delivery while in others new symptoms
may appear.
Hip dysplasia is an under recognised manifestation of CMT.6
(Early asymptomatic hip dysplasia was noted on X-ray in our first
patient.) Proximal weakness is rare but respiratory insufficiency has
been described in the latter stages of severe disease. This is
postulated as a disturbance in the diaphragmatic function7.
Diagnostic tests
The types of CMT may be differentiated by medical and family
history and examination, nerve biopsy, nerve conduction velocity
studies (NCV), electromyogram (EMG) and genetic studies.3-5 In
Type 1 CMT the NCV is slow <38m/sec i.e. similar to unmyelinated
nerves. In Type 2 NCV is within normal limits but with low amplitude.
The EMG has a characteristic pattern as a consequence of
abnormal nerves that innervate the muscle. Electrophysiologic
abnormalities may precede clinical symptoms by 2 years but the
severity of the disease does not correlate with the degree of
conduction slowing. Biopsy of the sural nerve may be helpful.
Typically the nerve in type 1 has a decreased number of myelinated
fibres and the hypertrophic changes resemble an “onion bulb”
histologically.
Genetic studies
Classification is based on inheritance patterns and genetic studies.2,4
CMT is caused by mutations in the encoding genes for peripheral
myelin protein, predominantly PMP22 or the MPZ genes, which are
necessary for the normal function of peripheral nerves.2-4 Absence
of these genes leads to demyelination. Broadly speaking about 60-
80% have Type 1 CMT which affects the myelin sheath (PMP22
gene) and 5-15% have Type 2 which affects the axons (MPZ gene).
Inheritance is autosomal dominant. Type 1 can be further
subdivided by genetic studies; Type 1A for example has the defect
on chromosome 17, while in Type 1B the defect is on chromosome
1.3,4 An extensive description of the genetic classification is beyond
the scope of this article but a simplified clinical classification is
shown in Table 1.
Figure 1: The typical foot deformity of a child with CMT prior to
surgery (case 1)
Figure 2: The deformed foot of case 2 showing evidence of extensive
surgical reconstruction. Despite the reconstruction this adolescent
had significant pain limiting his activity and requiring chronic pain
management.
Table 1: Classification of hereditary sensory motor neuropathies or
CMT disease
Type Pathology Clinical features
CMT 1 Demyelination Autosomal dominant, commonest
Weakness, atrophy, sensory loss in legs
Delayed nerve conduction
Multiple genetic subtypes
CMT 2 Neuronal disorder Autonomic dominant
Decreased amplitude of CMAP
Distal weakness
CMT 3 Severe demyelination Dejerine-Sottas Rare
Infantile onset
Delayed milestones -motor skills
Severe
CMT 4 Demyelination Autosomal recessive. Rare
Several types, Leg weakness
Onset childhood or adolescence
CMT X Defect in X-linked dominant Male>female
communication Moderate to severe
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An autosomal recessive form, type 4, is rare and
genetically heterogenous. A rarer more severe form, Dejerine-
Sottas disease is sometimes referred to as Type 3 disease.
There is a rarer X-linked dominant and recessive form of the
disease due to mutations in the gene encoding the gap
junction protein, connexion 32. Some 30 different genetic
subtypes have been identified by DNA studies.2-4
Outcome
There is no cure for CMT but physiotherapy, occupational
therapy, orthopaedic devices or surgery can help affected
individuals cope with the disabling symptoms of the disease. The
degree of disability is unpredictable between and within families;
even identical twins may be differently affected. Some may have
very mild forms and never seek medical attention while others
are severely handicapped. Life expectancy is normal.
Paradoxically, despite the peripheral neuropathy, some patients
may require chronic pain management for severe pain.
Anaesthetic considerations
Some concern has been expressed about the use of muscle
relaxants and regional anaesthesia in these patients.
Both depolarising and non-depolarising muscle relaxants
have been used with few problems. Suxamethonium has not
caused problems in stable patients. Similarly there is little
evidence that these patients are sensitive to non-depolarising
muscle relaxants, 8-10 although Brian et al expressed concern
in one case report in a patient with advanced disease11. In a
recent study on five children with CMT, aged 7-12 years, the
clinical duration of mivacurium-induced neuromuscular block
was similar to that in normal children.8
The use of regional anaesthesia in patients with pre-
existing neurological disorders is controversial.
Anaesthesiologists fear possible exacerbation of the basic
neurological disease. Controlled studies in affected
individuals evaluating the potential risks in different
neurological disorders are lacking. Epidural anaesthesia and
spinal block have been used for orthopaedic procedures 12
and caesarean section11,13,14 without exacerbation of the
disease or other problems. Neither of our patients reported
any problems following a single shot popliteal block or a
continuous popliteal nerve block using a 23G catheter for 48
hours.
Sensitivity to thiopentone was reported in 20 patients with
CMT compared to a control group.15. This has not been
reported with other induction agents. Total intravenous
anaesthesia (TIVA) has been used (propofol / fentanyl and
alfentanil)9,16. No problems or undue sensitivity were reported.
As this is a peripheral nerve disorder an association with
malignant hyperthermia seems unlikely. In a retrospective
review of 86 CMT cases, Antognini reported the use of
suxamethonium in 41 patients and triggering agents
(halothane) in 77 patients without problem.17
Other considerations include positioning during surgery
since nerve compression could worsen the underlying
neuropathy. Nitrous oxide, by inhibiting the cobalamin
dependent enzyme, methionine synthase, may be considered
neurotoxic in prolonged cases. No case of neurotoxicity has
been reported. Very rarely patients may have laryngeal
dysfunction and are prone to aspiration. Laryngeal dysfunction
may be recognised by voice changes.
Musculoskeletal pain can be treated with paracetamol or
non-steroidal anti-inflammatory agents (NSAIDS). Neuropathic
pain may respond to tricyclic antidepressants, carbamazepine
or gabapentin.
Conclusion
Charcot-Marie-Tooth disease is a disease that is often under
diagnosed because the disability may be slight. The onset and
severity of the disease is variable. Concerns with regard to
regional anaesthesia, muscle relaxants and malignant
hyperthermia seem unfounded. Despite the sensory loss, pain
may significantly limit normal activity.
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